TickerFacts.

Nexentis Technologies Inc. (NXTS): Capital Expenditures

Annual figures by period end, from SEC filings.

$14.0K
Year ended 2025-12-31
-35.3%
3-year compound annual growth
$67.7K2018-12-31: $2.5K2019-12-31: $23.3K2021-12-31: $67.7K2022-12-31: $51.7K2025-12-31: $14.0K$14.0K
2018-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$14.0Kn/a2026-03-31, From 2025-01-01
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31$51.7K-23.7%2024-04-01, From 2022-01-01
2021-12-31$67.7Kn/a2023-03-27, From 2021-01-01
No annual figure between 2019-12-31 and 2021-12-31.
2019-12-31$23.3K+822.4%2021-03-29, From 2019-01-01
2018-12-31$2.5Kn/a2020-03-30, From 2018-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Nexentis Technologies Inc. (NXTS)2025-12-31$14.0Kn/a
Evofem Biosciences, Inc. (EVFM)2025-12-31$5.0K-64.3%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$1.0K-91.7%
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$12.0Kn/m
Lftd Partners Inc. (LIFD)2025-12-31$121.6K-61.2%
Genelux Corp (GNLX)2025-12-31$1.10M+188.2%
Moleculin Biotech, Inc. (MBRX)2025-12-31$0-100.0%
Allarity Therapeutics, Inc. (ALLR)2025-12-31$8.0K-97.3%
Gain Therapeutics, Inc. (GANX)2024-12-31$22.5K+46.5%

Compare NXTS, EVFM, EMMA, PHIO side by side · Screen every company in Pharmaceutical Preparations ↗